A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.


Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.

Sign up for our monthly newsletter and review of recent literature!




At the 45th World Conference on Lung Health, two new MDR-TB clinical trials were announced. The first, an expansion of the STREAM study called STREAM Stage 2 will compare a six-month bedaquiline containing regimen and a nine-month bedaquiline-containing regimen without an injectable to the current WHO standard of care and a modified Bangladesh regimen. STREAM Stage 2 will take place in Ethiopia, Mongolia, South Africa and Vietnam. The second new trial, NExT, will take place in South Africa and will compare a a 6-9 month injection-free regimen containing bedaquiline, linezolid, levofloxacin, ethionamide/high dose INH, and PZA to the current South African standard MDR-TB regimen. For more details visit our Clinical Trial Progress Report here.

Recent News and Announcements

New report estimates loss of up to $100 trillion by 2050 due to drug resistant infections

In a new report  by the Review on Antimicrobial Resistance entitled “Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations,” characterized drug resistant TB as a “broad public health issue for which resistance is a concern.” Overall, the report estimates that failure to address drug resistant infections will cause 10 million deaths […]

USAID and J&J sign MoU for $30 million donation of bedaquiline

Detailed in a press release from USAID, Janssen Therapeutics signed a memorandum of understanding to donate $30 million worth of bedaquiline over a 4 year period through USAID’s programs. Responses to the announcement have varied, with the Stop TB Partnership calling the donation a “gamechanger” and  Médecins Sans Frontières responding that drug donation are not […]

Open letter to Janssen Pharmaceuticals to reduce the price of bedaquiline

Several organizations and individuals came together in September to write a letter to Janssen Pharmaceuticals, the maker of bedaquiline, to lower pricing for all non-high-income countries. Although bedaquiline is the first new TB drug approved in 40 years, it is not accessible to patients and TB program who need it most. Following the letter, Janssen responded […]

New activist guides for linezolid and delamanid

Treatment Action Group has released two new guides for activists on the use of delamanid and linezolid. These resources are intended to guide activists in what they can do to ensure access, fair pricing and further research. Access the delamanid guide here and the linezolid guide here on Treatment Action Group’s website.

Novartis provides candidate drug compounds to the Global Alliance for TB Drug Development

Novartis has signed a licensing agreement with the Global Alliance for TB Drug Development  for compounds to fight tuberculosis discovered at Novartis Institutes for Tropical Diseases (NITD). Under this agreement, NITD will transfer its TB R&D program to the TB Alliance, including research, development, approval and distribution responsibilities. Read more on the Novartis website here.

Event Calendar

Social Media